References
- Suresh M, Lavanya P, Vasu K, et al. Synthesis and bioassay studies of 7-substituted pyrido[2,3-d]pyrimidines. J Chem Pharm Res. 2010;2:82–89.
- Cordeu L, Cubedo E, Bandres E, et al. Biological profile of new apoptotic agents based on 2,4-pyrido[2,3-d]pyrimidine derivatives. Bioorg Med Chem. 2007;15:1659–1669.
- Font M, Gonzalez A, Palop JA, et al. New insights into the structural requirements for pro-apoptotic agents based on 2, 4-diaminoquinazoline, 2,4 diaminopyri [2,3-d]pyrimidine and 2,4-diaminopyrimidine derivatives. Eur J Med Chem. 2011;46:3887–3899.
- Dorsey JF, Jove R, Kraker AJ, et al. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 2000;60:3127–3131.
- Deyanov AB, Niyazov RK, Nazmetdinov FY, et al. Synthesis and biological activity of amides and nitriles of 2-arylami-no-5-carboxy (carbethoxy)-6-methylnicotinic acids and 1-aryl-6-carbethoxy-7-methyl-4-oxo-1, 4-dihydro- pyrido[2,3-d]pyrimidines. Pharm Chem J. 1991;25:248–250.
- Grivsky EM, Lee S, Sigel CW, et al. Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine. J Med Chem. 1980;23:327–329.
- Thompson AM, Bridges AJ, Fry DW, et al. Tyrosine kinase inhibitors.7.7-ami-no-4-(phenylamino)-and7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J Med Chem. 1995;38:3780–3788.
- Donkor IO, Klein CL, Liang L, et al. Synthesis and antimicrobial activity of 6,7-annulated pyrido[2,3-d]pyrimidines. J Pharm Sci. 1995;84:661–664.
- Pastor A, Alajarin R, Vaquero JJ, et al. Synthesis and structure of new pyrido[2,3-d]pyrimidine derivatives with calcium channel antagonist activity. Tetrahedron. 1994;50:8085–8098.
- Agarwal A, Ashutosh R, Goyal N, et al. Dihydropyrido[2,3-d]pyrimidines as a new class of antileishmanial agents. Bioorg Med Chem. 2005;13:6678–6684.
- Fetsch PA, Abati A, Litman T, et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett. 2006;235:84–92.
- Diestra JE, Scheffer GL, Catala I, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol. 2002;198:213–219.
- Hansch C. Use of quantitative structure-activity relationships (QSAR) in drug design. Pharm Chem J. 1980;14:678–691.
- Elzahabi HAS, Nossier ES, Khalifa NM, et al. Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyri do[2,3-d]pyrimidine scaffold. J Enzyme Inhib Med Chem. 2018;33:546–557.
- Sayed MTE, Hussein HAR, Elebiary NM, et al. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: synthesis, biological screening and molecular modeling studies. Bioorg Chem. 2018;78:312–323.
- Sugunakala S, Selvaraj S. 2D QSAR and virtual screening based on pyridopyrimidine analogs of epidermal growth factor receptor tyrosine kinase. Curr Comput Aided Drug Des. 2016;12:229–240.
- Krapf MK, Gallus J, Vahdati S, et al. New inhibitors of breast cancer resistance protein (ABCG2) containing a 2,4-disubstituted pyridopyrimidine scaffold. J Med Chem. 2018;61:3389–3408.
- Cortes C, Vapnik V, Mach J. Support-vector networks. Mach Learn. 1995;20:273–297.
- Vapnik V. Statistical learning theory. New York (NY): Wiley;1998; p. 732.
- Smola AJ, Scholkopf B. A tutorial on support vector regression. Stat Comput. 2004;14:199–222.
- Kuntz ID, Blaney JM, Oatley SJ, et al. A geometric approach to macromolecule-ligand interactions. JMB. 1982;161:269–288.